Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 8/20 | 0.51 |
| ▸ | DRD4 | P21917 | 8/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19035631 | 0.95 | DRD2 (0.52) | HRH3DRD2DRD4HTR1ADPP4 | |
| SCHEMBL81439 | 0.83 | HRH3 (0.46) | HRH3DRD2DRD4HTR1AHDAC1 | |
| SCHEMBL19035590 | 0.79 | DPP4 (0.50) | DRD2DRD4HTR1ADPP4DPP8 | |
| SCHEMBL19035629 | 0.78 | LMNA (0.52) | DRD2DRD4HTR1ADPP4DPP8 | |
| SCHEMBL81674 | 0.78 | OGG1 (0.47) | HRH3DRD2DRD4HTR1A | |
| SCHEMBL19035556 | 0.75 | HRH3 (0.51) | HRH3DPP4DPP8DPP7HDAC1 | |
| SCHEMBL12663049 | 0.75 | L3MBTL3 (0.64) | HRH3DRD2DRD4 | |
| SCHEMBL64843 | 0.74 | DRD4 (0.52) | HRH3DRD2DRD4HTR1AHDAC1 | |
| SCHEMBL5745416 | 0.74 | DRD4 (0.65) | DRD2DRD4HTR1A | |
| SCHEMBL9698828 | 0.74 | DRD4 (0.65) | DRD2DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | HRH3 3986/4885DRD2 3950/4885DRD4 3701/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HRH3 3902/4885DRD2 4450/4885DRD4 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.